IMMUNITYBIO, INC. Retained Earnings
IMMUNITYBIO, INC. (IBRX) had Retained Earnings of -$4.59 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$4.59B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$4.36B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$3.73B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$3.66B.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$4.59B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$4.36B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | -$3.73B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | -$3.66B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$3.60B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$3.50B 10-Q · filed 2025-05-12 | |
| 2024-12-31 | -$3.38B 10-K · filed 2026-02-23 | |
| 2024-09-30 | -$3.32B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$3.23B 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$3.10B 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$2.96B 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$2.73B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$2.63B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$2.49B 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$2.38B 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$2.27B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$2.16B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$2.06B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$1.96B 10-K · filed 2023-03-01 | |
| 2021-09-30 | -$1.87B 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$1.78B 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$1.69B 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$1.62B 10-K · filed 2022-03-01 | -$754.57M 10-K · filed 2021-03-04 |
| 2020-09-30 | -$722.44M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$700.67M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | -$680.57M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$1.39B 8-K/A · filed 2021-04-22 | -$662.19M 10-K · filed 2020-03-25 |
| 2019-09-30 | -$646.55M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | -$630.97M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | -$613.79M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$594.98M 10-K · filed 2020-03-25 | |
| 2018-09-30 | -$577.41M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | -$553.78M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | -$526.05M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | -$498.71M 10-K · filed 2019-03-13 | |
| 2017-09-30 | -$471.45M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$447.49M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | -$412.63M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | -$387.06M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$358.88M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$324.40M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$281.03M 10-Q · filed 2016-05-16 | |
| 2016-01-01 | $31.00M 10-Q · filed 2017-11-07 | |
| 2015-12-31 | -$250.38M 10-K · filed 2017-03-15 | |
| 2015-09-30 | -$172.72M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$130.00M 10-Q · filed 2015-09-10 | |
| 2014-12-31 | -$12.74M 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |